Unaudited Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (32,066)	$ (13,945)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	87	39
Stock-based compensation expenses	3,279	792
Change in fair value of preferred stock purchase right liability		980
Change in fair value of preferred stock warrant liability		105
Common stock issued in exchange for services		3
Noncash interest expense		508
Changes in operating assets and liabilities:
Accounts receivable	(209)	113
Prepaid expenses and other current assets	388	(4,258)
Other assets		(468)
Accounts payable	746	609
Accrued compensation	(3,762)	(1,119)
Accrued expenses and other current liabilities	3,879	(1,051)
Payable to PLI	192	(897)
Deferred revenue	(1,937)	(405)
Operating lease right-of-use assets and liabilities, net	15
Net cash used in operating activities	(29,388)	(18,994)
Cash flows from investing activities
Purchase of property and equipment	(955)	(298)
Net cash used in investing activities	(955)	(298)
Cash flows from financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs		73,749
Proceeds from sale of common stock in initial public offering		218,500
Payment of financing costs		(16,001)
Deferred financing costs	(226)
Proceeds from issuance of common stock upon stock option exercises	349	74
Net cash provided by financing activities	123	276,322
Net increase in cash and cash equivalents	(30,220)	257,030
Cash and cash equivalents at beginning of period	257,254	54,201
Cash and cash equivalents cash at end of period	227,034	311,231
Supplemental schedule of non-cash investing and financing activities
Conversion of convertible preferred stock into common stock upon completion of initial public offering		210,810
Reclassification of preferred stock purchase right liability to equity due to issuance of Series D convertible preferred stock		4,880
Reclassification of warrant liability to equity due to conversion from preferred stock warrant to common stock warrant upon completion of initial public offering		169
Issuance of Series D-2 convertible preferred stock for the settlement of deferred purchase price		6,144
Financing costs incurred, but not paid, included in accrued expenses and accounts payable	339	1,209
Vesting of early exercised stock options	6	9
Costs incurred, but not paid, in connection with capital expenditures included in accounts payable	$ 291	$ 237